Validated quantitative needs assessment differences in the management of children with central nervous system cancer between Brazil, an upper middle‐income country, and the United States of America, a high income country

2021 ◽  
Author(s):  
Allison N. Fischer ◽  
Roberto Roecker ◽  
Nasjla Saba da Silva ◽  
Sergio Cavalheiro ◽  
Jonathan L. Finlay ◽  
...  
Author(s):  
EV Walker ◽  
F Davis ◽  

The Canadian Brain Tumour Registry (CBTR) project was established in 2016 with the aim of enhancing infrastructure for surveillance and clinical research to improve health outcomes for brain tumour patients in Canada. We present a national surveillance report on malignant primary brain and central nervous system (CNS) tumours diagnosed in the Canadian population from 2009-2013. Patients were identified through the Canadian Cancer Registry (CCR); an administrative dataset that includes cancer incidence data from all provinces/territories in Canada. Cancer diagnoses are coded using the ICD-O3 system. Tumour types were classified by site and histology using The Central Brain Tumour Registry of the United States definitions. Incidence rates (IR) and 95% confidence intervals (CI) were calculated per 100,000 person-years and standardized to the 2011 census population age-distribution. Overall, 12,115 malignant brain and CNS tumours were diagnosed in the Canadian population from 2009-2013 (IR:8.43;95%CI:8.28,8.58). Of these, 6,845 were diagnosed in males (IR:9.72;95%CI:9.49,9.95) and 5,270 in females (IR:7.20;95%CI:7.00,7.39). The most common histology overall was glioblastoma (IR:4.06;95%CI:3.95,4.16). Among those aged 0-19 years, 1,130 malignant brain and CNS tumours were diagnosed from 2009-2013 (IR:3.36;95%CI:3.16,3.56). Of these, 625 were diagnosed in males (IR:3.32;95%CI:3.34,3.92) and 505 in females (IR:3.08;95%CI:2.81,3.36). The most common histology among the paediatric population was pilocytic astrocytoma (IR:0.73;95%CI:0.64,0.83). The presentation will include: IRs for other histologies, the geographic distribution of cases and a comparison between Canada and the United States.


2017 ◽  
Vol 19 (suppl_5) ◽  
pp. v1-v88 ◽  
Author(s):  
Quinn T Ostrom ◽  
Haley Gittleman ◽  
Peter Liao ◽  
Toni Vecchione-Koval ◽  
Yingli Wolinsky ◽  
...  

2021 ◽  
pp. 1-13
Author(s):  
Hamid Reza Saeidi Borojeni ◽  
Farid Najafi ◽  
Fatemeh Khosravi Shadmani ◽  
Zahra Darabi ◽  
Mitra Darbandi ◽  
...  

<b><i>Background:</i></b> Primary brain tumors are among the main causes of death. This study aimed to determine the epidemiological features of the brain and central nervous system cancer in the Middle East and North Africa (MENA) region. <b><i>Methods:</i></b> In this study, data of the Global Burden of Disease (GBD) study were used to estimate the incidence, prevalence, deaths, disability-adjusted life years (DALYs), and mortality in 21 countries in the MENA region from 1990 to 2019 based on age and sex. The percentage of the changes of epidemiologic indicators was calculated between 1990 and 2019. <b><i>Results:</i></b> Palestine and Turkey had the highest rate of brain and central nervous system cancer in 2019. Saudi Arabia, Oman, Iraq, and Lebanon had the highest percentage of incidence rate changes from 1990 to 2019. The prevalence of brain and central nervous system cancer in the MENA region was increased from 7.51 (95% CI: 4.95–11.01) in 1990 to 16.45 (95% CI: 10.83–19.54) in 2019 (percentage of changes = 54.35%). The standardized age mortality rate in the MENA region was increased by 2.7% in 2019 compared to that in 1990. The rate of standardized age of DALY per 100,000 individuals in the MENA region decreased from 135.09 (95% CI: 92.57–199.92) in 1990 to 128.34 (95% CI: 87.81–151.3) in 2019. <b><i>Conclusion:</i></b> The incidence rate, prevalence, and standardized age mortality (per 100,000) had increased significantly in the MENA region in 2019 compared to those in 1990. Focusing on the diversity of the estimates of such indices in different countries of MENA can lead to the identification of important risk factors for brain cancer in future studies.


Sign in / Sign up

Export Citation Format

Share Document